ZoBio

ZoBio is a biotechnology startup with the slogan "The Integrated Fragment Discovery Engine". Founded in 2004, the company offers innovative "gene to structure" research services for early stage drug discovery. ZoBio specializes in four key areas: enabling proteins for biophysical and structural biology studies, screening fragment libraries for selective ligands for pharmaceutical targets, providing 3D structural information on complexes of ligands bound to a protein, and advancing fragment "hits" through medicinal chemistry expertise. The company's proprietary technologies include Protein Domain Trapping for screening variants, TINS NMR screening technology, SPR, and high-concentration functional assays. ZoBio also offers structural information from protein NMR and crystallography, as well as medicinal chemistry focused on bridging the gap between fragment and hit. The focus on "crystallography" quality proteins and the ability to tackle structurally unprecedented and challenging proteins sets ZoBio apart in the industry. ZoBio operates within the biotechnology and healthcare industries and is currently privately held and self-funded. Although specific headquarters and latest investment details are not provided, the company's innovative approach and expertise in fragment-based drug discovery make it an intriguing prospect for potential venture capital investment.